The BPDF, part of the College of Engineering at the University of Nebraska, develops vaccines and biotherapeutics derived from recombinant yeast and bacterial expression systems under current Good Manufacturing Practices and Good Laboratory Practices.
Wallace Buchholz joins UNL’s BPDF as director
Wallace Buchholz has been named director of the Biological Process Development Facility (BPDF). Read more.
The BPDF is:
- A leading expert in the recombinant expression system (Pichia pastoris) used to express the Botulinum vaccines.
- One of the few University facilities working in the area of recombinant proteins.
- Focused on Phase I/II clinical material, allowing rapid development of new processes and production of therapeutic proteins.
The BPDF specializes in the process development and cGMP manufacturing of recombinant proteins from bacterial, yeast and fungal systems.
Serving both the public and private sector, our products range from vaccines against biological warfare agents to biotherapeutics for the treatment of cancer, AIDS and other illnesses.
BPDF clients include USAMRIID & DVC/NIAID, Emergent Biosolutions, and the Mintaka Foundation.
The cGMP pilot plant accommodates both recombinant bacteria and yeast expression systems at the 150 L-scale (working volume). Designed and built by AES CleanTechnology (clean rooms) and BioKinetics (process piping), the facility has state-of-the-art cGMP utilities, an established QA department, environmental monitoring, and a GLP compliant QC laboratory. Read more about cGMP.
Mintaka Foundation funds BPDF to create HIV resistant topical cream for women.
With $3.8 million in new funding from the Mintaka Foundation of Medical Research supported by the Wellcome Trust, the UNL BPDF is developing a process to manufacture a stable and affordable microbicide to protect women from contracting and spreading HIV. Read more about the contract.